F-Prime Capital

F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it has a strong legacy rooted in Fidelity Investments, which has been a significant player in asset management since 1946. F Prime focuses on early-stage investments in North America and Europe, primarily in the healthcare, life sciences, technology, therapeutics, fashion, medtech, and health information technology sectors. The firm operates several funds, including those dedicated to healthcare, oncology, life sciences, and health technology services. F Prime Capital Partners emphasizes supporting entrepreneurs without the pressure of external fundraising, allowing them to concentrate on identifying and nurturing promising companies.

Abdul Abdirahman

Principal

Jessica Alston

Partner

Nikhil Ananth

Senior Associate

Hannah Arnold

Principal

Raj Basak

Associate

Thomas R. Beck

Executive Partner

Sam Bisbee

Venture Partner

Eric Blatte

Venture Partner

Carl Byers

Partner

Kevin Chu

Principal

Lucille Conroy

Senior Associate

Brett Cook

Partner

Shervin Ghaemmagham

Operating Partner

Shervin Ghaemmaghami

Investor

Benjamin Gorman

Venture Partner

Ben Gorman

Principal

David Jegen

Managing Partner

Stephen Knight

President and Managing Partner

Sarah Lamont

Senior Associate

Erica Lee

Senior Associate

Connie Li

Associate

Jon Lim

Partner

Jonathan P. Lim

Managing Partner

Jiang Lin

Principal

Muzammil Mansuri

Venture Partner

Julia McDowell

Venture Partner

Betsy Mulé

Senior Associate

Alex Pasteur

Partner

Ketan Patel

Partner

Sachin Patodia

Partner

Cameron Raglin

Associate

Brett J. Rome

Venture Partner

Steve Schultz

Venture Partner

Mihir Shah

Venture Partner

Siyu Shi

Associate

Nihal Sinha

Partner

Anastasiya Sybirna

Senior Associate

Martin Taylor

Senior Associate

Gaurav Tuli

Partner

Jennifer Uhrig

Senior Managing Director

Bala Varadhan

Principal

Robert Weisskoff

Partner

Stacie Weninger

Executive Director

Alex Wong

Associate

Rocio Wu

Principal

Chong Xu

Partner

Brian Yordy

Principal

Fang Yu

Partner

Michael Zheng

Venture Partner

Past deals in Growth Stage

1upHealth

Series C in 2023
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, founded in 2017. It operates a health data aggregation and centralization platform that facilitates the secure transmission of medical data between health systems and consumer applications. The platform consolidates health information from various electronic medical record systems, allowing users to control and share their digital health records with healthcare providers. Additionally, it enables providers to access and query the most current patient data from multiple connected health systems. The platform also supports software developers by providing access to clinical data from various clinics and hospitals, ultimately aiming to improve healthcare outcomes and reduce costs through better data utilization.

Canoe

Series B in 2023
Canoe Software Inc. develops an artificial intelligence-based software solution for financial document and data management, primarily targeting allocators and investors in alternative assets. Founded in 2013 and based in New York, the company specializes in automating the collection, organization, and categorization of investment documents. Its software enables users to extract unstructured data from these documents and integrate it into various accounting and reporting platforms, enhancing data accuracy and operational efficiency. Canoe’s services cater to a diverse clientele, including single and multi-family offices, endowments, foundations, pensions, investment consultants, wealth managers, and financial institutions. By transforming PDF reports into actionable data, Canoe aims to improve the post-investment operational, monitoring, and reporting experience for its clients.

Vendr

Series B in 2022
Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.

Proximie

Series C in 2022
Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

RightHand Robotics

Series C in 2022
RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.

Equip Health

Series B in 2022
Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

LogixBoard

Series B in 2022
Logixboard, Inc. is a Seattle-based company founded in 2016 that offers a cloud platform designed to enhance transparency and communication for freight forwarders. The platform addresses inefficiencies in the $2 trillion freight forwarding industry, where many firms rely on outdated methods such as paper, spreadsheets, and email for tracking shipments. By integrating with existing back-office applications, Logixboard's solution serves as a digital customer engagement layer, enabling freight forwarders to streamline their operations and improve customer service. The platform empowers companies to manage and control their freight operations more effectively, ultimately reducing costs and increasing efficiency in a traditionally low-tech industry.

Leyden Labs

Series B in 2022
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Papaya

Series B in 2021
Papaya is a developer of an online mobile bill payment application that simplifies financial transactions for users. The application supports various payment methods, including debit and credit cards and direct bank account transfers. It prioritizes security by encrypting personal information and payment data, ensuring compliance with HIPAA and PCI standards. In addition to its bill payment services, Papaya operates as an electronic money platform, offering digital solutions, online banking, and international payment services. This combination of features enables users to manage their financial activities efficiently and securely.

Lighthouse

Series B in 2021
Lighthouse, operating under the name OTA Insight Ltd, specializes in providing cloud-based business intelligence solutions for the hospitality industry. Founded in 2012 and based in London, the company offers a suite of tools including Rate Insight, Parity Insight, and Revenue Insight, which help hoteliers make informed revenue and distribution decisions. These solutions utilize advanced data systems and forecasting algorithms to deliver real-time market demand forecasts, rate intelligence, and ranking analytics. With a strong emphasis on customer support, OTA Insight’s platform integrates seamlessly with various hotel management systems and data providers, supporting over 50,000 properties in 168 countries. Recognized as a leader in hospitality business intelligence, the company has garnered accolades and continues to empower hoteliers to optimize occupancy rates and enhance profitability.

AppliedVR

Series B in 2021
AppliedVR, Inc. specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, specifically for managing pain and anxiety in various settings such as hospitals and surgery centers across the United States. Founded in 2013 and based in Los Angeles, the company has established partnerships with leading healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles. Its therapeutic virtual reality platform has been utilized by over 20,000 patients in more than 250 hospitals and in eight countries. The technology is designed to address both acute and chronic pain, as well as anxiety related to medical procedures, offering clinically validated, on-demand solutions. Inspired by extensive academic research, AppliedVR seeks to redefine pain management practices in clinical environments and at home, aiming to establish itself as a leading digital health solution provider in this field.

Notable

Series B in 2021
Notable is an AI-powered healthcare startup focused on enhancing physician-patient interactions by automating and digitizing the recording of medical visits. The company's platform utilizes natural language processing and voice recognition technology to automatically capture and structure conversations between doctors and patients, facilitating the seamless update of electronic health records. Additionally, Notable's system recommends appropriate billing codes, streamlining administrative tasks for healthcare providers. By improving the efficiency of these interactions, Notable aims to allow physicians to dedicate more time to patient care rather than paperwork.

Stride Health

Series C in 2021
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.

Funnel

Series C in 2021
Funnel Operation AB, founded in 2014 and headquartered in Stockholm, Sweden, specializes in marketing analytics and reporting software designed to automate data collection for marketers. The company's platform integrates with over 400 marketing and advertising sources, allowing users to streamline data feeding into various tools such as Business Intelligence systems, Data Warehouses, Google Sheets, Google Data Studio, and Google Analytics. Funnel's offerings include dashboards and reports for simplified marketing analysis, a data studio connector for aggregating marketing data, and APIs that facilitate data collection and distribution. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B companies, mobile applications, and gaming firms, helping them manage advertising performance data effectively and gain insights for informed decision-making.

Centivo

Venture Round in 2021
Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.

NOCD

Series B in 2021
NOCD Inc. is a Chicago-based company that operates a mobile application designed to connect individuals with obsessive-compulsive disorder (OCD) to licensed mental health practitioners. Founded in 2014, the platform leverages cognitive behavioral therapy techniques, specifically exposure and response prevention exercises, to help users manage their symptoms. The application facilitates face-to-face video therapy sessions with therapists who specialize in OCD, while also providing 24/7 support through self-help tools and peer communities. NOCD aims to enhance the treatment experience for OCD patients by offering clinically supported resources and a comprehensive online platform dedicated to treatment and self-monitoring.

Gyenno Science

Series B in 2021
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.

Oviva

Series C in 2021
Oviva is a digital health company providing medically-oriented nutritional counseling services in Switzerland, Germany, and the United Kingdom. Founded in 2013 and headquartered in Ingenbohl, Switzerland, Oviva offers personalized behavior change programs aimed at managing diet and lifestyle-related health issues like obesity and diabetes. Their services are delivered through a network of qualified dietitians who work with clients both in clinics and remotely. The company has developed a smartphone application that allows users to engage with their dietitian, maintain a food diary, set health goals, and access tailored educational materials. This technology-enabled approach helps patients achieve better health outcomes while reducing the need for in-person appointments, ultimately lowering healthcare costs by preventing complications associated with these conditions.

Carrot Fertility

Series C in 2021
Carrot Fertility, Inc. provides comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey globally. Founded in 2015 and headquartered in San Francisco, the company offers a range of services, including egg freezing, in vitro fertilization, adoption, donor, and gestational carrier services. Additionally, it features Carrot Rx, which facilitates a premium pharmacy experience for fertility medications, and Carrot Pregnancy, providing virtual access to experts and on-demand content. Carrot Card is a flexible benefits debit card that allows employees to pay for their care. By partnering with modern companies, Carrot Fertility enables organizations to customize fertility benefits that deliver financial, medical, and emotional support to employees seeking to become parents. The company also has offices in major cities around the world, including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Innovusion

Series B in 2021
Innovusion, Inc. is a prominent developer of image grade LiDAR sensor systems, specifically designed for level 4 and 5 autonomous vehicles and advanced driver-assistance systems (ADAS). Founded in 2016 and based in Sunnyvale, California, Innovusion focuses on providing solutions that combine range, resolution, and hardware-accelerated sensor fusion within a compact and cost-effective framework. This unique approach makes their products suitable for the most demanding applications in the autonomous driving sector. As a venture-backed company, Innovusion is positioned at the forefront of innovation in the rapidly evolving automotive technology landscape.

MoEngage

Series C in 2021
MoEngage, Inc. is a customer engagement and analytics platform that focuses on enhancing customer retention and lifetime value for businesses. Founded in 2014 and headquartered in San Francisco, California, MoEngage offers cloud-based marketing services that enable companies to execute campaigns across multiple channels, including in-app messaging, web, and SMS. Its platform utilizes machine learning to optimize customer interactions, providing tools for user intelligence, push notifications, in-app recommendations, and email communications, all accessible through a single dashboard. The company serves various industries, including e-commerce, telecommunications, travel and hospitality, and banking and finance. MoEngage also has a strategic partnership with Vidora, Inc., and maintains additional offices in several international locations, including Bengaluru, Singapore, London, Jakarta, Bangkok, Ho Chi Minh City, and Berlin.

SonderMind

Series C in 2021
SonderMind LLC, founded in 2017 and based in Denver, Colorado, operates a digital platform that connects individuals with mental health professionals for both telehealth and in-person sessions. The company offers a comprehensive directory of therapists who provide services for a range of mental health issues, including anxiety, depression, PTSD, and more. SonderMind's platform aims to make behavioral health services more accessible and user-friendly, allowing consumers to easily find and schedule appointments with well-matched therapists. By streamlining the connection between clients and providers, SonderMind enhances the therapeutic experience while allowing therapists to concentrate on patient care without being burdened by administrative tasks.

Embark

Series B in 2021
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Castor

Series B in 2021
Castor is an international health-tech company that offers a cloud-based clinical data platform designed to streamline the clinical trial process for researchers around the world. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries and has facilitated more than 4,000 studies across diverse therapeutic areas such as diabetes, cardiovascular diseases, rare diseases, infectious diseases, and oncology. Researchers using Castor generate substantial amounts of data from both traditional and remote trials, having reached significant milestones of 180 million data points and 2 million enrolled patients. The company's mission is to enhance the reusability of research data, supporting AI-driven clinical trials and ultimately maximizing the impact of data to improve medical research globally.

Prime Medicine

Series B in 2021
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Orient Speech Therapy

Series C in 2021
Provider of speech and language therapy services intended for stunted children with speech disorder. The company provides early screening, clinical diagnosis, and therapeutic interventions to children with autism or speech disorder, enabling children to speak and communicate better.

Pulmocide

Series C in 2021
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Affinia Therapeutics

Series B in 2021
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

CareStack

Series C in 2021
CareStack is a cloud-based platform designed to meet the comprehensive administrative and clinical needs of dental practices. It integrates various functionalities, including practice management, patient engagement, scheduling, telehealth conferencing, charting, automated reminders, claims processing, and business analytics, all within a single interface. This all-in-one solution is particularly beneficial for large and growing dental practices, helping them enhance productivity, reduce operational costs, and improve patient care. By centralizing and automating key processes, CareStack aims to elevate the financial success of dental offices while ensuring a streamlined experience for both patients and staff.

Proximie

Series B in 2021
Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.

1upHealth

Series B in 2021
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, founded in 2017. It operates a health data aggregation and centralization platform that facilitates the secure transmission of medical data between health systems and consumer applications. The platform consolidates health information from various electronic medical record systems, allowing users to control and share their digital health records with healthcare providers. Additionally, it enables providers to access and query the most current patient data from multiple connected health systems. The platform also supports software developers by providing access to clinical data from various clinics and hospitals, ultimately aiming to improve healthcare outcomes and reduce costs through better data utilization.

Zenflow

Series B in 2021
Zenflow, Inc. is a medical device company based in San Francisco, California, founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists. The company focuses on developing and marketing a spring device designed to provide relief for permanent benign prostatic hyperplasia (BPH) symptoms in men. Zenflow's product addresses urinary obstruction without damaging surrounding tissues, offering a novel solution for patients and healthcare providers. The founders were motivated by the frustrations experienced by patients with existing treatment options, aiming to fulfill a significant unmet clinical need in urology.

Firefly Health

Series B in 2021
Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.

OZiva

Series B in 2021
OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.

Innovusion

Series B in 2021
Innovusion, Inc. is a prominent developer of image grade LiDAR sensor systems, specifically designed for level 4 and 5 autonomous vehicles and advanced driver-assistance systems (ADAS). Founded in 2016 and based in Sunnyvale, California, Innovusion focuses on providing solutions that combine range, resolution, and hardware-accelerated sensor fusion within a compact and cost-effective framework. This unique approach makes their products suitable for the most demanding applications in the autonomous driving sector. As a venture-backed company, Innovusion is positioned at the forefront of innovation in the rapidly evolving automotive technology landscape.

LakeShore Biopharma

Series B in 2021
Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Cohort

Series B in 2021
Cohort, Inc. specializes in developing software that enhances chronic care management and clinical trials. The company's clinical AI and natural language processing technology analyzes electronic health records (EHR), extracting insights from diagnostics, medications, and clinical notes to provide tailored context for patients and their conditions. Cohort's platform streamlines the identification and enrollment of eligible patients, generates care plans automatically, and facilitates compliance and billing processes. By offering these solutions, Cohort enables primary care providers to improve the scale and efficiency of their chronic care management programs while also enhancing the identification and enrollment process for clinical trials. The company is headquartered in New York, with an additional office in San Francisco.

Metcela

Series B in 2021
Metcela Inc. specializes in developing fibroblast-based therapies for cardiac diseases, focusing on regenerative medicine for conditions such as Ischemic Heart Disease. Founded in 2016 and based in Kawasaki-shi, Japan, the company utilizes VCAM-1-positive cardiac fibroblasts derived from patients' own cells. This innovative approach aims to replenish and restore damaged cardiac muscle and its surrounding microenvironment, enhancing the heart's natural healing capabilities. By repairing rather than replacing damaged cells, Metcela seeks to provide effective and cost-efficient treatments for heart failure, offering new hope for patients suffering from cardiac ailments.

Centivo

Series B in 2020
Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.

Odaseva

Series B in 2020
Odaseva is a unified cloud data protection, compliance, and operations platform for enterprises running Salesforce. The company delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions). Odaseva was developed for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures.

SnapDocs

Series C in 2020
Snapdocs, Inc. is a real estate technology company that provides a digital platform designed to streamline the mortgage closing process. Founded in 2012 and based in San Francisco, California, Snapdocs connects lenders, title and escrow companies, notary publics, and home buyers to enhance collaboration and efficiency in real estate transactions. The platform features advanced automation and standardized workflows, allowing participants to choose their preferred closing methods while improving accuracy and consumer satisfaction. It also enables notary signing agents to showcase their qualifications, helping them attract potential clients. By simplifying mortgage loan closings and improving the overall borrower experience, Snapdocs empowers its users to operate more effectively and transparently in a competitive market.

Carrot Fertility

Series B in 2020
Carrot Fertility, Inc. provides comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey globally. Founded in 2015 and headquartered in San Francisco, the company offers a range of services, including egg freezing, in vitro fertilization, adoption, donor, and gestational carrier services. Additionally, it features Carrot Rx, which facilitates a premium pharmacy experience for fertility medications, and Carrot Pregnancy, providing virtual access to experts and on-demand content. Carrot Card is a flexible benefits debit card that allows employees to pay for their care. By partnering with modern companies, Carrot Fertility enables organizations to customize fertility benefits that deliver financial, medical, and emotional support to employees seeking to become parents. The company also has offices in major cities around the world, including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Checkmate Pharmaceuticals

Series C in 2020
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

PatientPing

Series C in 2020
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.

NodThera

Series B in 2020
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Avalyn Pharma

Series B in 2020
Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Rallybio

Series B in 2020
Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.

SonderMind

Series B in 2020
SonderMind LLC, founded in 2017 and based in Denver, Colorado, operates a digital platform that connects individuals with mental health professionals for both telehealth and in-person sessions. The company offers a comprehensive directory of therapists who provide services for a range of mental health issues, including anxiety, depression, PTSD, and more. SonderMind's platform aims to make behavioral health services more accessible and user-friendly, allowing consumers to easily find and schedule appointments with well-matched therapists. By streamlining the connection between clients and providers, SonderMind enhances the therapeutic experience while allowing therapists to concentrate on patient care without being burdened by administrative tasks.

Devoted

Series C in 2020
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Devoted

Series C in 2020
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Xilio Therapeutics

Series B in 2020
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Whatfix

Series C in 2020
Whatfix is a digital adoption platform that assists enterprises in enhancing their training and support initiatives by delivering contextual information in a user-friendly manner. The platform employs real-time interactive guidance technology to provide personalized, in-app user assistance, transforming traditional training and support methods. By offering just-in-time guidance, Whatfix enables users to complete tasks more efficiently across various applications, including web, desktop, and mobile. This approach fosters a unified digital workflow and self-help experience, leading to increased user adoption and productivity. Clients benefit from improved process compliance, reduced time for completing critical operations, and access to data-driven insights that support informed decision-making.

MoEngage

Series C in 2020
MoEngage, Inc. is a customer engagement and analytics platform that focuses on enhancing customer retention and lifetime value for businesses. Founded in 2014 and headquartered in San Francisco, California, MoEngage offers cloud-based marketing services that enable companies to execute campaigns across multiple channels, including in-app messaging, web, and SMS. Its platform utilizes machine learning to optimize customer interactions, providing tools for user intelligence, push notifications, in-app recommendations, and email communications, all accessible through a single dashboard. The company serves various industries, including e-commerce, telecommunications, travel and hospitality, and banking and finance. MoEngage also has a strategic partnership with Vidora, Inc., and maintains additional offices in several international locations, including Bengaluru, Singapore, London, Jakarta, Bangkok, Ho Chi Minh City, and Berlin.

WelbeHealth

Series C in 2020
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

BenchSci

Series B in 2020
BenchSci Analytics Inc., founded in 2015 and based in Toronto, Canada, offers a research intelligence platform that leverages artificial intelligence and machine learning to assist scientists in navigating scientific literature for antibody usage data. By translating both closed and open-access data, the platform provides tailored recommendations for experiments, ultimately aiming to enhance the efficiency and success of biomedical research. BenchSci's technology is utilized by leading pharmaceutical companies and research institutions worldwide, significantly contributing to the acceleration of scientific discoveries. The company aspires to reduce the time it takes to bring medicines to patients by 50% by 2025, reflecting its commitment to advancing healthcare through innovative research solutions. BenchSci has garnered recognition as a top growth company and a favorable workplace, reflecting its impact and culture in the biotech industry.

Funnel

Series B in 2020
Funnel Operation AB, founded in 2014 and headquartered in Stockholm, Sweden, specializes in marketing analytics and reporting software designed to automate data collection for marketers. The company's platform integrates with over 400 marketing and advertising sources, allowing users to streamline data feeding into various tools such as Business Intelligence systems, Data Warehouses, Google Sheets, Google Data Studio, and Google Analytics. Funnel's offerings include dashboards and reports for simplified marketing analysis, a data studio connector for aggregating marketing data, and APIs that facilitate data collection and distribution. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B companies, mobile applications, and gaming firms, helping them manage advertising performance data effectively and gain insights for informed decision-making.

Oviva

Series B in 2020
Oviva is a digital health company providing medically-oriented nutritional counseling services in Switzerland, Germany, and the United Kingdom. Founded in 2013 and headquartered in Ingenbohl, Switzerland, Oviva offers personalized behavior change programs aimed at managing diet and lifestyle-related health issues like obesity and diabetes. Their services are delivered through a network of qualified dietitians who work with clients both in clinics and remotely. The company has developed a smartphone application that allows users to engage with their dietitian, maintain a food diary, set health goals, and access tailored educational materials. This technology-enabled approach helps patients achieve better health outcomes while reducing the need for in-person appointments, ultimately lowering healthcare costs by preventing complications associated with these conditions.

Wellframe

Series C in 2019
Wellframe Inc. is a digital health management company based in Boston, Massachusetts, that specializes in care management solutions and digital concierge services. Founded in 2011, Wellframe develops mobile patient engagement software that enhances care management by connecting patients with their care teams through a user-friendly mobile application. The platform utilizes real-time member-generated data and artificial intelligence to create personalized care protocols and facilitate two-way communication, allowing for timely interventions and better patient monitoring. Wellframe's offerings include health plan solutions, such as daily health reporting, care team dashboards, and omni-channel communication tools, as well as operational services like system integration and analytics. Additionally, the company provides strategic consulting and change management services to help healthcare organizations improve their care delivery and patient engagement processes.

SnapDocs

Series B in 2019
Snapdocs, Inc. is a real estate technology company that provides a digital platform designed to streamline the mortgage closing process. Founded in 2012 and based in San Francisco, California, Snapdocs connects lenders, title and escrow companies, notary publics, and home buyers to enhance collaboration and efficiency in real estate transactions. The platform features advanced automation and standardized workflows, allowing participants to choose their preferred closing methods while improving accuracy and consumer satisfaction. It also enables notary signing agents to showcase their qualifications, helping them attract potential clients. By simplifying mortgage loan closings and improving the overall borrower experience, Snapdocs empowers its users to operate more effectively and transparently in a competitive market.

CareStack

Series B in 2019
CareStack is a cloud-based platform designed to meet the comprehensive administrative and clinical needs of dental practices. It integrates various functionalities, including practice management, patient engagement, scheduling, telehealth conferencing, charting, automated reminders, claims processing, and business analytics, all within a single interface. This all-in-one solution is particularly beneficial for large and growing dental practices, helping them enhance productivity, reduce operational costs, and improve patient care. By centralizing and automating key processes, CareStack aims to elevate the financial success of dental offices while ensuring a streamlined experience for both patients and staff.

Recurly

Series C in 2019
Recurly, Inc. specializes in providing subscription management and billing solutions designed to optimize revenue growth for businesses across various industries, including digital media, streaming, publishing, SaaS, and consumer goods. Founded in 2009 and headquartered in San Francisco, California, with additional offices in Boulder and New Orleans, the company offers a comprehensive platform that automates recurring billing processes, enhances payment acceptance, and reduces subscriber churn through effective card recycling strategies. Recurly's services allow businesses to quickly implement subscription billing systems, manage customer-related billing issues effortlessly, and gain actionable insights into their operations. As a level 1 PCI compliant service provider, Recurly also helps clients minimize costs and obligations associated with payment security. By streamlining these functions, Recurly enables businesses to focus on growth and improve their overall subscriber economics.

InSilico Medicine

Series B in 2019
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

InSilico Medicine

Series B in 2019
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Protenus

Series C in 2019
Protenus, Inc. is a Baltimore-based company that specializes in a healthcare compliance analytics platform designed to protect patient privacy and secure health data. Utilizing artificial intelligence, the platform audits every access to patient records across leading health systems in the United States. It enables healthcare organizations to gain comprehensive insights into the usage of health data, proactively identifying risks such as inappropriate access to patient information and potential theft or misuse of controlled substances by staff. By alerting compliance teams to policy violations and other anomalous behaviors, Protenus empowers hospitals to make informed decisions to enhance data protection and safeguard their institutions. The company, which was established in 2014 and previously known as Protenus, LLC, focuses on reducing risk and optimizing operational efficiency for its partner hospitals.

Radico

Series C in 2019
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.

Buoy Health

Series B in 2019
Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Optimus Ride

Series B in 2019
Optimus Ride is a self-driving vehicle company based in Boston, Massachusetts, that focuses on developing technologies for efficient, sustainable, and equitable mobility systems. As a spinoff from the Massachusetts Institute of Technology, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and mobility-on-demand systems. Its technology integrates advancements in sensor fusion, mapping, computer vision, and machine learning, tailored for geofenced environments. The team comprises individuals with extensive industrial and entrepreneurial experience in areas such as manufacturing robotics, urban design, and shared vehicle fleet management, enabling diverse applications ranging from commercial vessel operations to transit solutions.

RiskLens

Series B in 2019
The leading provider of cyber risk management software, RiskLens empowers business executives, risk officers and CISOs to manage their organization's cyber risk from the business perspective by quantifying it in financial terms. RiskLens was founded in 2011 and is headquartered in Spokane, Washington.

ABK Biomedical

Series B in 2019
ABK Biomedical Inc., founded in 2012 and based in Halifax, Canada, develops innovative embolotherapeutic products aimed at treating uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company focuses on enhancing interventional radiology procedures, particularly embolization, by combining clinical market insights with advanced biomaterials. ABK Biomedical's flagship product is a novel radiopaque microsphere designed to improve the targeting of tumor blood vessels and tissue. This technology not only aids in the standardization and optimization of minimally invasive therapies but also facilitates personalized treatment options for patients with complex conditions. Through its commitment to advancing embolotherapy, ABK Biomedical seeks to transform patient care in the field of interventional radiology.

Vestwell

Series B in 2019
Vestwell is a digital retirement platform founded in 2016 and headquartered in New York, New York. It simplifies the offering and administration of 401(k) plans for advisors, employers, and employees by eliminating traditional challenges associated with retirement plan management. The platform features seamless plan design, automated onboarding, and streamlined administration, all while providing flexible investment strategies at competitive prices. By serving as a single point of contact, Vestwell enhances the retirement planning experience, ensuring that both plan sponsors and participants have their interests prioritized. Additionally, the platform supports registered investment advisors with automated compliance options tailored to the specific rules and regulations governing defined contributions.

Artemis Health

Series C in 2019
Artemis Health Inc. is a health data analytics company that specializes in providing self-insured employers with actionable insights into their employee benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company offers a platform that helps employers identify issues within their benefits programs, pinpoint opportunities for improvement, and track the effectiveness of implemented solutions. By leveraging their own benefits data, employers can make informed decisions aimed at reducing healthcare expenditures while enhancing the quality of health and wellness coverage for their employees. Artemis Health's approach aims to address inefficiencies in the U.S. healthcare system, ultimately supporting organizations in optimizing their benefit offerings.

Whatfix

Series B in 2019
Whatfix is a digital adoption platform that assists enterprises in enhancing their training and support initiatives by delivering contextual information in a user-friendly manner. The platform employs real-time interactive guidance technology to provide personalized, in-app user assistance, transforming traditional training and support methods. By offering just-in-time guidance, Whatfix enables users to complete tasks more efficiently across various applications, including web, desktop, and mobile. This approach fosters a unified digital workflow and self-help experience, leading to increased user adoption and productivity. Clients benefit from improved process compliance, reduced time for completing critical operations, and access to data-driven insights that support informed decision-making.

Beam Therapeutics

Series B in 2019
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

Singular Genomics

Venture Round in 2019
Singular Genomics is a biotechnology company based in La Jolla, California, founded in 2016. It specializes in developing advanced gene sequencing technologies utilizing fluorescing molecular tags and novel next-generation sequencing and multiomics approaches. The company aims to empower researchers and clinicians through its innovative products, which include the G4 Sequencing Platform for next-generation sequencing and the PX Integrated Solution for single-cell analysis, spatial analysis, and proteomics. Singular Genomics is strategically located within a prominent biotech hub, adjacent to esteemed institutions such as the Salk Institute and UC San Diego, fostering collaboration and innovation in the rapidly growing genomics field. Its product offerings cater to a wide range of applications, including basic biology, oncology, and immunology, positioning the company as a key player in the life sciences sector.

Checkmate Pharmaceuticals

Series C in 2018
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

Genomics

Series B in 2018
Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Avidity Biosciences

Series B in 2018
Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.

Devoted

Series B in 2018
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

PharmEasy

Series C in 2018
PharmEasy is a leading pharmacy aggregator in India that operates an online drug delivery platform aimed at enhancing the supply chain of pharmaceuticals. By digitizing the process, it connects patients with local pharmacy stores and diagnostic centers, ensuring they can easily access a wide range of medicines and healthcare products. The platform is designed to make healthcare services more accessible and affordable, emphasizing the importance of good health for everyone. Through its services, PharmEasy strives to simplify the healthcare experience for patients, allowing them to fulfill their medical needs efficiently.

Axoni

Series B in 2018
Axoni is a New York-based technology firm focused on capital markets, specializing in distributed ledger solutions. Founded in 2013 by experts in distributed ledger technology and cryptography, Axoni serves major financial institutions and capital markets service providers. The company's offerings include the deployment of distributed ledger technology, custom smart contract development, and advanced analytics tools. Their software integrates traditional financial technologies with blockchain capabilities, providing market information and in-depth trend analysis. This comprehensive approach enables investment funders, exchange operators, and professional traders to enhance their systems for managing legal records, lifecycle events, and cash flow calculations.

RiskRecon

Series B in 2018
RiskRecon is the only continuous vendor monitoring solution that delivers risk-prioritized action plans custom-tuned to match your risk priorities, providing the world’s easiest path to understanding and acting on third-party cyber risk. Partner with RiskRecon to build your scalable, third-party risk management program to realize dramatically better risk outcomes. To learn more about RiskRecon’s approach, request a demo or visit the website at www.riskrecon.com.

Radico

Series B in 2018
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.

WelbeHealth

Series B in 2018
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

Unison

Series B in 2018
Unison is a provider of home-ownership investments that enables individuals to finance their homes without the burden of interest or monthly payments. Founded in 2004 and headquartered in San Francisco, California, Unison offers long-term investments in residential properties through innovative programs. These programs allow homeowners to share in the appreciation or depreciation of their property's value when they sell, creating a unique financial solution for those looking to purchase homes. By combining fintech origination capabilities with investment management, Unison aims to make homeownership more accessible and sustainable for a broader range of applicants.

Benchling

Series B in 2018
Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.

Tempest Therapeutics

Series B in 2018
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Protenus

Series B in 2018
Protenus, Inc. is a Baltimore-based company that specializes in a healthcare compliance analytics platform designed to protect patient privacy and secure health data. Utilizing artificial intelligence, the platform audits every access to patient records across leading health systems in the United States. It enables healthcare organizations to gain comprehensive insights into the usage of health data, proactively identifying risks such as inappropriate access to patient information and potential theft or misuse of controlled substances by staff. By alerting compliance teams to policy violations and other anomalous behaviors, Protenus empowers hospitals to make informed decisions to enhance data protection and safeguard their institutions. The company, which was established in 2014 and previously known as Protenus, LLC, focuses on reducing risk and optimizing operational efficiency for its partner hospitals.

Quartet Health

Series C in 2018
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

Orchard Therapeutics

Series B in 2017
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.

Orient Speech Therapy

Series B in 2017
Provider of speech and language therapy services intended for stunted children with speech disorder. The company provides early screening, clinical diagnosis, and therapeutic interventions to children with autism or speech disorder, enabling children to speak and communicate better.

Semma Therapeutics

Series B in 2017
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Threat Stack

Series C in 2017
Threat Stack specializes in providing security solutions tailored for cloud infrastructure, enabling DevOps and SecOps teams to innovate and scale securely. The Threat Stack Cloud Security Platform and Cloud SecOps Program are designed to address complex cloud security needs by delivering continuous security monitoring and risk assessment. This approach helps organizations identify and verify insider threats, external attacks, and compliance gaps in real-time. By focusing on cloud, hybrid-cloud, and containerized environments, Threat Stack empowers security and operations teams to effectively manage risk and compliance across their entire infrastructure.

Stride Health

Series B in 2017
Stride Health, Inc. operates a health benefits platform tailored for independent workers and part-time employees in the United States. The platform enables users to select and enroll in various affordable health coverage options, including dental, vision, and prescription insurance plans. Stride Health simplifies the process of finding suitable health insurance by providing personalized recommendations and tax deduction support, thereby helping customers maximize their take-home pay. The company, originally known as Covered, Inc., rebranded to Stride Health in March 2013 and has since been based in San Francisco, California. Through its services, Stride Health aims to make healthcare accessible and manageable for its users.

Artemis Health

Series B in 2017
Artemis Health Inc. is a health data analytics company that specializes in providing self-insured employers with actionable insights into their employee benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company offers a platform that helps employers identify issues within their benefits programs, pinpoint opportunities for improvement, and track the effectiveness of implemented solutions. By leveraging their own benefits data, employers can make informed decisions aimed at reducing healthcare expenditures while enhancing the quality of health and wellness coverage for their employees. Artemis Health's approach aims to address inefficiencies in the U.S. healthcare system, ultimately supporting organizations in optimizing their benefit offerings.

Amphora Medical

Series B in 2017
Amphora Medical, Inc. is a Minnesota-based company that develops medical devices focused on treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is working on a novel cystoscopic device designed to enhance bladder function and improve the quality of life for patients suffering from OAB. Utilizing minimally invasive procedures and advanced cystoscopic technology, Amphora Medical aims to provide effective solutions for individuals affected by this condition.

VYNE Therapeutics

Series C in 2017
VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.

Wellframe

Series B in 2017
Wellframe Inc. is a digital health management company based in Boston, Massachusetts, that specializes in care management solutions and digital concierge services. Founded in 2011, Wellframe develops mobile patient engagement software that enhances care management by connecting patients with their care teams through a user-friendly mobile application. The platform utilizes real-time member-generated data and artificial intelligence to create personalized care protocols and facilitate two-way communication, allowing for timely interventions and better patient monitoring. Wellframe's offerings include health plan solutions, such as daily health reporting, care team dashboards, and omni-channel communication tools, as well as operational services like system integration and analytics. Additionally, the company provides strategic consulting and change management services to help healthcare organizations improve their care delivery and patient engagement processes.

Checkmate Pharmaceuticals

Series B in 2017
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

Quovo

Series B in 2017
Quovo Inc. is a financial data platform that specializes in providing connectivity and insights for consumer financial accounts from over 14,000 institutions. Founded in 2009 and based in New York, Quovo's technology enables businesses to retrieve, organize, and analyze data, thereby enhancing their customer relationships and improving service personalization. The platform offers automated portfolio data management, including features like data normalization, reconciliation, and client onboarding through Autoverified Micro-deposits. Quovo serves a diverse clientele, including small- and mid-sized investors, endowments, family offices, and financial advisors. Its solutions are utilized by notable fintech companies and retail banks, making it a vital player in the digital finance landscape. In January 2019, Quovo became a subsidiary of Plaid Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.